-
Research and reconstructions
Thursday, December 5, 2019In an interview with Dr Soosan Jacob, Prof Madeleine Zetterberg describes the Swedish Opthalmological Society’s annual meeting.
-
Wine in paradise
Thursday, December 5, 2019Illustration by Eoin Coveney What is the #1 red grape variety in Italy, as measured by total wine production?” I asked, as the nine other members took their seats, pen and paper in one hand and a Chianti in the other. The first Friday of the month had finally arrived, and for us, that means: […]
-
Driving Revenues
Thursday, December 5, 2019Carones and Malley challenged surgeons to assess their effectiveness in various aspects of their clinics.
-
Gender inequality in ophthalmology
Tuesday, October 1, 2019Improving women’s experiences in the workplace improves life for everyone
-
Consultations project wins Innovation Prize
Monday, September 16, 2019Julien Buratto won the inaugural Innovation Prize at the ESCRS Practice Management and Development Programme
-
Delving deeper into refractive surgery
Sunday, September 1, 2019Refractive surgery is, for the most part, spectacularly successful and proceeds complication-free.
-
Software update
Sunday, September 1, 2019OD-OS has released a new software update for its Navilas 577s.
-
A re-evaluation of a constant threat
Sunday, September 1, 2019The risk of endophthalmitis was, until relatively recently, on every cataract surgeon’s mind during and after every single procedure.
-
Take off your mask
Sunday, September 1, 2019Leigh Spielberg MD reflects on the momentary blindness he experienced during a scuba diving lesson
-
Aerie in Europe
Sunday, September 1, 2019Aerie’s recently completed state-of-the-art sterile fill facility in Athlone, Ireland With US Food and Drug Administration approval of its first product in December 2017, newcomer Aerie Pharmaceuticals made history. The company’s proprietary Rho kinase (ROCK) inhibitor eye drop, Rhopressa (netarsudil ophthalmic solution) 0.02%, represented the first new drug class approved in the US for reducing […]
